• Enabling

    Enabling

    Knowledge, Skills and Big Data

  • Innovation and Creation

    Innovation and Creation

    Open Mindset and Think Disruptive

  • Planning Forward

    Planning Forward

    Focus, Ensuring Performance and Success

  • Growth and Sustainability

    Growth and Sustainability

    Assuring Shareholder Values and Returns

  • Staff and Family

    Staff and Family

    High Impact Performance and Quality Life

  • Corporate Social Responsibilities

    Corporate Social Responsibilities

    Living Harmoniously with Nature and Communities

Showing posts with label Business. Show all posts
Showing posts with label Business. Show all posts

Malaysia 2020: Expected GDP growth at 4.8%



The government remains steadfast in the belief that Malaysia will achieve an economic growth of 4.8%  in 2020 as it expects to see positive effects from its development spending latest by June 2020, according to Finance Minister, YB Lim Guan Eng.

“We are confident about maintaining the projection, supported by a rebound in the commodity prices, growth in investment spurred especially by government spending, as well as expectations of a positive outcome to the US-China trade war, ” he told Bernama.

He was commenting on the downward revisions of the 2020 growth projections by economists. Last month, the World Bank Group trimmed its forecast of the country’s gross domestic product (GDP) growth for this year to 4.5% from 4.6% previously on weakening investment and trade activity recorded in the third quarter of last year.

“There was no problem in terms of development expenditure for ongoing projects, but new projects would have to be brought forward to 2020 and added to Budget 2020 (for new developments), ” he pointed out. 

On the US-China trade war, Lim said the end of the dispute would be a booster or catalyst to spur the economy.“As an exporting economy, Malaysia will benefit. 

 /theSTAR 01-01-2020

Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.


Read more

Private doctors and dentists' consultation fees deregulated



Doctors and dentists in private clinics and hospitals can soon determine their own consultation fees, following a decision by the Cabinet to deregulate the fee structures and let free market reign.

The consultation fees must be displayed clearly so that patients are aware of the fees before getting treatment.The latest decision will strengthen the consumers' power to choose their doctors.

If patients are not happy with the charges or services received in any of the private facilities, they can lodge a complaint with the Private Medical Practice Control Section at ckaps.aduan@moh.my for further investigation.
Health Minister Datuk Seri Dr Dzulkefly Ahmad, who announced this, said the Cabinet had assessed the matter holistically and comprehensively as well as taken into consideration the recommendations from the National Cost of Living Council.
The Cabinet is also concerned about the need to amend the Seventh Schedule of the Private Healthcare Facilities and Services (Private Medical Clinics and Private Dental Clinics) Regulations 2006, which has not been amended since it was enforced in 2006, he said. 
"As such, the Cabinet has agreed to abolish the control over consultation fees under Act 586.
The abolition of the fee control will include all registered facilities (in the Seventh Schedule) and licensed facilities (13th Schedule), said Dzulkefly.
The fees for GPs and dentists, as stated in the Seventh Schedule, have not changed in 27 years and doctors have been calling for the fee harmonisation as provided for in the 13th Schedule of the regulations when it was revised in 2013.
In 2013, the consultation fee was gazetted for medical officers working in private hospitals under the 13th Schedule,except for GPs and dentists working in private clinics under the Seventh Schedule.
The current fees of RM10 to RM35 for GPs and dentists practising in clinics have not been revised since 1992 while medical officers at private hospitals who have the same qualifications have been charging between RM30 and RM125 per consultation.
/theSTAR 06-12-2019
Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.


Read more

Malaysia ranks 12th in World Bank’s Ease of doing Business



The "World Bank Doing Business 2020 Report" has ranked Malaysia in 12th position among 190 economies worldwide, an improvement from the 15th spot the previous year, says the International Trade and Industry Ministry.

Minister Datuk Darell Leiking said the improved ranking was due to the public and private sector members’ collaboration and commitment within the technical working groups under the Special Task Force to Facilitate Business (Pemudah) to improve the ease-of-doing-business environment.
“Malaysia Productivity Corporation (MPC)" as the Secretariat of Pemudah works closely with the respective technical working groups to initiate and monitor the implementation of the various improvement initiatives,” he said.
Darell said Pemudah consistently launches improvement initiatives that impact positively on the ease of doing business by promoting regulatory efficiency, productivity and good governance.
He said Malaysia’s improved performance in the Doing Business 2020 Report attests that the on-going reform initiatives are on the right track to further enhance competitiveness, productivity and governance in the ease of doing business as well as to promote investments, which will accelerate national economic development and prosperity.
The Doing Business Report surveys regulations governing business activities in the economies which are then ranked according to their ease of doing business scores based on quantitative indicators of the regulations.
The report measures the processes for business incorporation, getting a building permit, obtaining an electricity connection, transferring property, accessing credit, protecting minority investors, paying taxes, engaging in international trade, enforcing contracts and resolving insolvency.
/MM 24-10-2019
Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.

The Doing Business Report surveys regulations governing business activities in the economies which are then ranked according to their ease of doing business scores based on quantitative indicators of the regulations.



Read more

Top 10 Global Pharma companies in 2019:



The global pharmaceutical industry reached unprecedented heights in 2018, being estimated at an astounding USD1.11 trillion. By 2020, this figure is set to rise to USD1.43 trillion. 
With rising pressure to develop drugs to meet ever increasing global demand, pharmaceutical companies continue to work tirelessly to bring the most innovative and cutting-edge treatments to patients.
Being a research-driven industry, approximately USD150 billion is spent by pharmaceutical companies every year on research and development projects. Out of thousands of compounds, only a small percentage gain regulatory approval to be used by patients to treat disease and improve quality of life. 
However, in 2018, a record number of novel drugs developed by pharmaceutical companies across the globe were approved by various regulatory bodies. A large proportion were approved by the US regulatory body, the FDA, which approved 55 novel drugs and smashed its record for generic approvals (781 up from 763 in 2017).
Although the USA’s market share of the global pharmaceutical industry is worth over USD 341.1 billion, the Chinese, South East Asian, Eastern European and South American markets are beginning to emerge. For example, the Chinese market is rich with preclinical and early-phase drugs, and is a growing nucleus of biotech activity. 
The next few years will see global growth thanks to the increasing wealth worldwide, as well as increasing demand to maintain high levels of innovation to combat unmet medical need.
Proclinical has ranked the leading pharmaceutical companies according to 2018 revenue from their pharmaceutical segment only.  

1) Pfizer  

USD 53.7 billion

2) Roche

USD 45.6 billion

3) Johnson & Johnson 
USD 40.7 billion

4) Sanofi

USD 39.3 billion

5) Merck & Co 
USD 37.7 billion
6) Novartis
USD 34.9 billion

7) AbbVie

USD 32.8 billion

8) Amgen

USD 23.7 billion

9) GlaxoSmithKline (GSK)
USD 23 billion

10) Bristol-Myers Squibb (BMS) 

USD 22.6 billion

/proclinical 20-03-2019

Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.


Read more

Ministry of Health: "No hanky-panky in drug procurement"



The Health Ministry says allegations of drug supplies monopoly and corruption levelled against it are baseless.

However, the whistleblower who first made the allegation in June, expressed disappointment and  has given an update to The Star detailing the rising tender contracts value of drug supplies by the top six tendering agents.

A tendering agent, however, begged to differ, explaining that the procurement procedures were transparent and the use of agents was common even in other countries.

The real issue was whether tendering agents should be bumiputra agents only, he said.


On Friday (Oct 19), Health secretary-general Datuk Seri Dr Chen Chaw Min said  that the ministry had investigated the drug supply procurement procedures for hospitals and found they were carried out according to the  guidelines set by the Finance Ministry.

On the issue of the appointment of agents, involvement of politicians or senior government servants in procurement, as well as the monopoly claims, he said the matter had been referred to the Malaysian Anti-Corruption Agency (MACC) and the Malaysia Competition Commission (MyCC).

"So far, nothing out of ordinary has been reported against the ministry."

"With this statement, we hope that no parties will make any assumption or create confusion about the management of the procurement at the Health Ministry," Dr Chen said in a statement on Friday (Oct 19) in response to a Free Malaysia Today report.

The portal had reported that the whistleblower was disappointed with the lack of action after his revelation.

On June 13, The Star carried a report on the allegations in which the whistleblower provided details on high-ranking officials and companies linked to politicians said to have control over billions of  ringgit worth of medical supply to the Health Ministry.

A 12-page document was emailed to Health Minister Dr Dzulkefly Ahmad and forwarded to a few parties including The Star.

It said there were bid-rigging of open tender process, thus enabling the monopoly of medical supply.

In response to the ministry's statement on the matter, the whistleblower provided updates, saying that the top six tendering agents had, to-date, been awarded approximately RM5,934,877,317 or 92.21% of the approximate RM6,435,975,589 total tender contracts value.

The whistleblower said with the latest information, the amount was now approximately RM6.44bil for the period of 2010 to 2018 (and ongoing).

"Collectively the top six tendering agents were awarded approximately RM5,934,877,317 or 92.21% of the approximate RM6,435,975,589 total tender contracts value," he said.

The tendering agent, who disagrees with the accusations, said this was not evidence of wrong-doing, explaining that the procurement procedures were transparent and the use of an agents was common even in other countries.

The agent, who is not one of the top six, said he was surprised a pharmaceutical company would make such allegations because the procedures were transparent.

In fact, he said drug patent was the actual monopoly that is causing drug prices to be high - a legal monopoly according to the World Trade Organisation's agreement, of which Malaysia is a signatory.

Moreover, for some drugs, he said, direct negotiations were required because they were patented with no other companies producing them.

"Why would the government call for a tender if a product is patented? So, it would have to be direct negotiations," he said.

He said multinational companies might say they did not want a middle man, but a lot of countries had some sort of an agency arrangement.

Some companies were big enough to step up operations in Malaysia, some were not and would use the service of a tendering agent, he said.

"So, this requirement is actually global. Now, whether it needs to be a bumi agent or not is the bigger question.

"That is why I tell the MNCs to be clear of what they are against," he added.

He said because the six tendering companies had been around for a long time and pharmaceutical companies were happy with their services, they continue to use the tendering agents.

"If you are number 50 to 75, and you expect the licence to bring in money, then sorry, because none of the principals would want to deal with you," he said.

He said that the pharmaceutical company he represents once "got burnt" as the tendering agent did not pay up for some of the products it supplied.

"That's why I understand why MNCs are comfortable dealing with only certain agents," he said. 

/theSTAR 20-10-2018

Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.


Read more

CPTPP signed by 11 Countries





Trade Ministers from 11 Pacific Rim countries signed a sweeping free trade agreement on Thursday, 8th March 2018, to streamline trade and slash tariffs just hours before President Donald Trump announced his plans to impose new tariffs on aluminum and steel to protect U.S. producers.
The US withdrew from the Trans-Pacific Partnership (TPP) last year, causing fears that it would not prosper without its most influential country. But the remaining 11 members pressed ahead, saying they were showing resolve against protectionism through global trade.The Ministers dropped key provisions that the US had required on protection of intellectual property, among others. The renegotiated pact signed in Chile’s capital was also renamed the Comprehensive and Progressive Trans-Pacific Partnership (CPTPP).
“Despite the diverse and difficult challenges, the CPTPP is a historic achievement that creates free and fair 21st century rules in the Asia-Pacific region,” Japanese Economy Minister Toshimitsu Motegi said at a news conference after the signing.
The CPTPP that covers 500 million people includes Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam, which together account for 13 percent of the global economy. Its success highlights the isolation of the U.S. under Trump’s protectionist rhetoric on trade and his “America first” philosophy.
“It leaves the US at a disadvantage from both a trade and a broader strategic perspective,” said Joshua Meltzer, senior fellow in the global economy and development program at the Brookings Institution. “It is now a trade bloc that discriminates against the U.S.” Meltzer said the United States’ ability to shape the rules of trade in the Asia-Pacific region “is very much diminished.”
The US, originally the biggest TPP economy, was one of the trade deal’s strongest supporters before Trump took office. Trump has said he prefers country-to-country deals and is seeking to renegotiate several major trade agreements, including the North American Free Trade Agreement that includes the US, Mexico and Canada.
This is “a strong sign against the protectionist pressures, and in favor of a world open to free trade, without unilateral sanctions and the threat of trade wars,” Chilean Foreign Minister Heraldo Munoz said.
The EU threat and Trump’s impending announcement on the tariffs were expected to escalate the risk of a trade war, in which nations try to punish each other by hiking taxes on traded goods. Experts say that tends to harm both exporting nations as well as importing countries’ consumers, who face higher costs. The EU considers itself to be caught in the crossfire of a trade dispute, in which Trump has mainly singled out China for being unfair in its commercial deals.
The original TPP was conceived by the U.S. as a counterweight to China’s growing economic influence through a robust trading bloc that excluded the Asian giant. The thinking was that China would have an incentive to open its market and liberalize its policies in an effort to eventually qualify for TPP membership.
/Time 08-03-2018

Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.


Read more

TPP targetted to be signed in March 2018



Malaysia has welcomed a breakthrough among trade negotiators of the remaining 11 countries of the Trans-Pacific Partnership in Tokyo, clearing the way for a revised agreement to be signed in early March 2018
International Trade and Industry Minister Datuk Seri Mustapa Moha­med said the free trade agreement, now known as the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP), is a high-quality agreement with a combined GDP worth US$11 trillion (RM42.9 trillion), covering a 476 million population and a 15% share of global trade volume.
“The signing of this agreement will be a significant boost to global trade and open doors for Malay­sian companies to expand their presence in the overseas market."
“We expect additional jobs to be created as a result of further investments that will come due to the improved trading and investing environment under the CPTPP. We are satisfied with the outcome of this meeting and our negotiators have once again successfully defended Malaysia’s interests,” Mus­­­ta­pa said in a statement.
The signing of the deal will be done without the United States, which has abandoned it under President Donald Trump.
The CPTPP involves Australia, Bru­­nei, Canada, Chile, Japan, Malay­sia, Mexico, New Zealand, Peru, Singapore and Vietnam.
The agreement will incorporate all commitments from the original TPP, except for a limited number of provisions suspended temporarily and some remaining issues to be finalised.
Mustapa listed four issues, including Malaysia’s request for additional flexibility for the oil and gas sector under state-owned enterprises chapter, which were resolved.
“Malaysia’s request for additional flexibility to conduct preferential purchases for the upstream oil and gas sector will now commence on the date of entry instead of the date of signing."
“The other issues (involving other countries) are market access for the coal industry, trade sanctions related to dispute settlement and exception to cultural industries."
“Before the Tokyo meeting, there were 20 provisions that will be suspended under the CPTPP."
“The suspension would mean that these provisions will not be implemented until all CPTPP mem­ber countries agree to lift this suspension.
“The Tokyo meeting has agreed to add two more suspensions into the list – making it a total of 22 suspensions. One of them was on the additional flexibility for Malaysia in the oil and gas sector, after the relentless pursuit and consistent fight put forth by our negotiating team on this matter. The other one was on market access for Brunei’s coal industry,” the statement added.
According to Japanese media reports, nearly two-dozen stipulations sought by the US in the original TPP deal were shelved after Washington withdrew.

Some members sought easier terms on labour rights and state-owned companies, but it’s unclear how far the changes will go in watering down what was proclaimed by the Obama administration to be a “gold standard” for 21st century trade rules.
Japan’s top trade negotiator, Toshimitsu Motegi, said he hoped to expand the membership of the TPP and encourage a US return to the pact.
/theSTAR 25-01-2018
 
Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.


Read more

Healthcare Budget 2018: Quick glance






/iMoney 27-10-2017

Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.


Read more

Malaysia: Growth of Private Health and Social Sector



Malaysia’s private healthcare and social work services sector has been growing by leaps and bounds, the Department of Statistics 2016 Economic Census revealed.
The country has some 14,930 private establishments providing general and specialised medical services, dental services, hospital services, dialysis centres, child day-care, residential care and maternity homes among others, in 2015.
These establishments contributed RM16.8bil to Malaysia’s economy in 2015, compared to RM10.4bil from 9,152 such establishments in 2010.
Some 121,088 people were employed in this sector in 2015, out of which 88.5% are full-time employees, 2.2% are paid part-time employees while the remaining 9.3% are owners or unpaid family workers.
Female workers outnumbered male wor­kers in all qualifications, except at the post-graduate level where more men (5,000) were employed than women (2,874). 
Most health and social workers possessed at least an SPM or SPM (V) certificate (26.5%), diploma qualification (28.7%) or advanced diploma or Bachelor’s degree (23.8%). Only 2.6% or 3,222 of the workers had below SPM or SPM (V) qualification.
Overall the workers took home RM3.68bil in salaries and wages in 2015, compared to RM2.1bil in 2010.
Employees in private hospital services topped the salary list at RM1.84bil in 2015, followed by employees in general medical services at RM737mil and specialised medical services at RM300.6mil.
The average monthly salary in the private health and social work services sector in 2015 was RM2,795.
Employees serving in specialised medical services recorded the highest average monthly salary at RM3,352, followed by hospital services at RM3,317 and medical laboratories at RM3,065.
Selangor has the highest number of esta­blishments providing health and social work services at 3,883, followed by Kuala Lumpur at 2,299 and Johor at 1,713 in 2015.
Women-owned establishments in this sector also increased from 3,122 in 2010 to 4,699 in 2015.
The highest increase in the number of women-owned outfits between 2010 and 2015 was recorded in child day-care activities (784), other human health services (172) and residential care activities (138).
theSTAR 19-10-2017

Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.


Read more

Hovid Bhd: Privatisation



Major shareholder David Ho Sue San, working with private equity (PE) firm TAEL Two Partners Ltd, have made a general offer for Hovid shares at 38 sen apiece in a bid to take the company private.

The exercise sees a special vehicle called Fajar Astoria Sdn Bhd, set up by TAEL to undertake the offer with Ho. TAEL is part of the TAEL Partners group, established in 2007 as a South East Asian-centric PE firm.

The takeover offer will also involve Ho and Fajar Astoria buying up the group’s outstanding five-year warrants at 20 sen per warrant.

Based on Hovid’s announcement on Monday, Ho, who is also the chairman and managing director, holds a 33.72% stake or 276.80 million shares and 43.57% or 140.39 million warrants in Hovid.

The offerors are proposing to buy 181.84 million units of the outstanding warrants, which represents about 56.43% of the total warrants.The warrants expire on June 5, 2018 and have an exercise price of RM0.18 per warrant.

Going back to the buyout offer, the condition of 90% acceptances means this: Ho will need acceptances of 90% of the 66.28% of Hovid shares he does not own. This translates into a total of 59% holding of the company (which works to around 484 million Hovid shares) accepting Ho’s offer.

Hence the takeover offer will fail, if Ho does not achieve this level of acceptances. However, it is interesting to note that the offerors have also stated that they reserve the right to review the level of acceptance to less than the 90% level. It will be interesting to see if they lower the condition at some point during the life of the offer.

Ho, a pharmacy graduate, is also the founder of Hovid. He took over his father’s herbal tea business. The business flourished until he bought over a building in Ipoh and named it Ho Yan Hor Medical Hall. This was later renamed as Ho Yan Hor Sdn Bhd and today it is known as Hovid Bhd.

Aside from generic drugs and dietary supplements under its own Hovid brandname, the company also does contract manufacturing for other drugmakers. About 95% of its revenue is said to be derived from the Hovid brand name.

He later founded another company called Carotech Bhd, which went public on Bursa Malaysia’s Mesdaq market, now known as ACE Market, in 2005.

The Ipoh-based Carotech specialised in extracting tocotrienol (vitamin E) from crude palm oil and became well-known globally, conquering about 80% of global palm vitamen E market share. But Carotech’s fortunes dwindled and was delisted on May 11, 2012 for failing to submit its regularisation plan to Bursa Securities for approval within the stipulated time.

A series of events took place after this where Ho and other directors at Carotech and Hovid were publicly reprimanded by the authorities for breaching listing requirements with regard to both companies’ financial results.

So why does Ho want to privatise Hovid? The offerors did not indicate the rationale for the privatisation.

Nevertheless, it is pertinent to note that Hovid had slipped into the red in financial year ended June 30, 2017 (FY17).

The company posted a net loss of RM1.53mil from net profit of RM17.9mil, against a 10% drop in revenue at RM169.94mil from RM189.03mil. It has RM15.9mil in cash, with debt of RM65.6mil as at June 30, 2017.

The earnings, according to Hovid, was dragged by the disruption in manufacturing activities arising from the revocation of its manufacturing licences of two plants. This subsequently affected its sales volume and led to higher operating costs from improvements on quality systems and production processes.

Hovid’s manufacturing licences of two plants were revoked after an audit by the National Pharmaceutical Regulatory Agency (NPRA) revealed that its Pharmaceutical Quality System were not in compliance with the latest Good Manufacturing Practice. The revocation of licence was linked to Hovid recalling its hypertension pills, Ternolol 50mg on Jan 5, which triggered the audit by the NPRA.

Hovid’s earnings before interest, tax, depreciation and amortisation (Ebitda) margin also suffered for the fourth quarter FY17, shrinking to a mere 4.2%, from fourth quarter of FY16’s 13.5%.

The company managed to obtain the license for its Chemor plant in May, but the other plant requires some physical changes, according to reports.

At the current share price of 36 sen, just two sen short of the offer price, Hovid is trading at a forward price-to-earnings ratio of 21.18 times.

Hovid’s 52-week high of 38 sen was about a year ago on Oct 14, 2016, while its 52-week low was on Jan 10, 2017 at 24 sen. However, its highest was last seen on April 21, 2015 at 53.7 sen. The stock has risen 16.13% from Oct 3rd’s 31 sen, before Hovid’s privatisation announcement.

In terms of assets, Hovid has about 16 properties and land worth some RM33mil, with the bulk last valued in June 2016. Of these, the ones valued the most include its Chemor plant and research and development centre worth RM27.15mil, a RM13.22mil pharmaceutical factory and office building in Ipoh and seven parcels of vacant land also in Ipoh worth RM11.5mil.

A month ago, CIMB Research maintained its “hold” rating on the stock, with a higher sum-of-parts based target price of 34 sen. The house cut its FY18-19 estimates by 16.3%-27.6% to account for lower production volume and further delays in the Chemor plant extension. The research house said Hovid was facing labour shortages that resulted in its less than optimal production volume.


theSTAR/14-10-2017

Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.


Read more

CCM: "De-gear" & Demerge



Chemical Company of Malaysia Bhd’s (CCM) defended the company’s demerger exercise as one that will not result in any losses to shareholders.

CCM group managing director Leonard Ariff Abdul Shatar acknowledged that it would take time for the market to digest the recently announced corporate exercise to de-gear and demerge from its profit-making pharmaceutical unit CCM Duopharma Biotech Bhd.

“We believe it will take time for the market to fully comprehend the corporate exercise because it involves a lot of moving parts. But our message is, shareholders will not lose out,” he said.

However, CCM’s shares fell 12 sen, or 7.1%, yesterday to close at RM1.57, effectively wiping out RM54.5mil from the company’s market capitalisation. CCM Duopharma’s shares, on the other hand, closed unchanged at RM2.11 yesterday.





A dealer reckoned that some shareholders did not like the dilutive aspect of the deal, as it involves a placement exercise. Others, the dealer said, could be selling on a knee-jerk reaction to the share consolidation element in the proposal.

Leonard Ariff pointed out that under the demerger exercise, entitled CCM shareholders – institutional and retail – would effectively get CCM Duopharma shares for free. The subsequent exercise to consolidate CCM shares from three to one, on the other hand, would ensure that the value of the company’s share remains intact.

“For investors who buy into CCM before the close of our book-building exercise, they will be getting CCM Duopharma’s shares for free,” he said.

On that note, he pointed out that shareholders who had previously bought into CCM for “cheaper” exposure to CCM Duopharma would now benefit through direct shareholding in the latter. “This means the dividend from CCM Duopharma will flow directly to them post-demerger without dilution through CCM,” Leonard Ariff said.

“The exercise to subsequently consolidate CCM shares from three to one is to ensure that they don’t lose any value, as the shares will effectively be based on the net asset of the reduced size of the company following the demerger exercise,” he added.

At present, Permodalan Nasional Bhd (PNB) owns about 70% of CCM, which, in turn, has a 73.4% stake in CCM Duopharma.

The proposed demerger announced on Wednesday would see CCM distribute its entire 73.4% stake in CCM Duopharma to its shareholders.This exercise would also involve a capital reduction in CCM’s share capital by about RM462.9mil. CCM announced that it would consolidate its shares on the basis of three to one. This exercise is expected to be completed by January 2018.

In addition, CCM also announced a de-gearing initiative, involving a plan to raise up to RM257.6mil through a private placement of up to 10% of its share capital and the disposal of three parcels of land measuring 70.93 acres in Shah Alam, Selangor. The proposed disposal of the Shah Alam land was deemed a divestment from its non-core assets.

According to Leonard Ariff, CCM expects to raise another gross proceeds of around RM65mil from the sale of its two other identified non-core assets, namely, the Nilai Industrial Land and the group’s 8.45% equity stake in Korea-listed PanGen Biotech Inc.

He said the imminent sale of the Nilai Industrial Land, which could raise about RM20mil based on the current book value, would be conducted through a tender process. Further announcements on the sale would be made by year-end.

As for the proposed sale of CCM’s stake in PanGen, which could raise about RM45mil, Leonard Ariff conceded that while the group had yet to identify a potential buyer, a deal could be concluded by next year.

He pointed out that the sale of the company’s non-core assets is part of a continuous de-gearing exercise to strengthen the group’s balance sheet.

“We will continue to divest from our non-core assets, which we define as those that do not give us revenue of income or dividends, until we achieve a healthy gearing... in absolute terms, our target is to reduce our total loans down to around RM100mil from the current level of RM440mil,” he added.

Under the proposed corporate exercise announced on Wednesday, CCM would undertake a private placement of up to 10% of its issued share capital and dispose of its three parcels of leasehold land measuring up to 70.93 acres in Shah Alam, Selangor, as part of a de-gearing exercise.

Leonard Ariff said CCM’s de-gearing exercise would result in substantial savings for the company.

“At present, we pay RM21mil annually in interest costs to service our debts; post de-gearing exercise, our interest costs would only be a quarter of that,” he pointed out.

CCM’s proposed private placement, which is scheduled to complete in October this year, is expected to raise up to RM67.6mil, while the disposal of land in Shah Alam, which is scheduled to complete in March 2018, to an independent third party would be at a cash consideration of RM190mil.The total proceeds from the fund-raising exercise and land sale would mainly be used to repay CCM’s borrowings.

Meanwhile, CCM’s proposal to distribute its entire 73.4% stake in CCM Duopharma to its shareholders - a move that would result in the demerger of the two companies – would allow the group to focus on managing the growth of its chemical products and polymer coating businesses. The exercise would benefit CCM’s shareholders by enabling them to participate directly in the equity of CCM Duopharma at no cost.

“The initiatives are a continuation of our strategic review which commenced in 2015 to house all of our pharmaceutical businesses under the CCM Duopharma umbrella, to exit from non-performing business segments, and strengthen our balance sheet to enable ample agility to pursue our capital expansion and a sustainable growth strategy for the future,” Leonard Ariff said.

“The proposed initiatives will lighten the balance sheet for CCM and give shareholders direct ownership in both CCM and CCM Duopharma, and participate directly in the growth of the two separate entities. It is expected that the restructuring will enable us to utilise our resources more effectively and efficiently, and promote strong growth for our chemicals and polymer businesses. It is part of CCM’s continuous effort to strive towards sustainability and achieve optimum development in moving forward and growing within a competitive business environment,” he added. 

/theSTAR 04-08-2017

Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.


Read more

Mercer's 2017: Quality of Living Rankings



Kuala Lumpur has been ranked the second best city in South-East Asia in Mercer's 2017 Quality of Living rankings, with Johor Baru in third place.

The annual survey by consulting firm Mercer, used by multinational companies to design expatriate packages, ranked Kuala Lumpur as second for the city with the best quality of life in South-East Asia, with a global ranking of 86 out of 231 cities surveyed.

In terms of Asian cities, Kuala Lumpur is ranked at No. 10, while Johor Baru, which is 103rd globally, is ranked at No. 14.

The Quality of Living survey looked at 10 categories including political and social environment, economic environment, natural environment, housing, health services, and education.

According to Mercer's 19th annual Quality of Living survey, Singapore is the best Southeast Asian city in terms of quality of living and has a global rank of 25.

Other key South-East Asian cities in the Quality of Living survey include Bangkok, which ranked fourth in the region and 131 globally, Manila (ranked fifth in South-East Asia and 135 globally, and Jakarta in sixth place, with a global rank of 143.

Other notable cities in Asia include Hong Kong (ranked 71 globally), Seoul (76), Taipei (85), Shanghai (102) and Beijing (119).

Five Japanese cities, meanwhile, top the ranking for East Asia. These are Tokyo (ranked 47 globally), Kobe (50), Yokohama (51), Osaka (60), and Nagoya (63).

Despite increased political and financial volatility in Europe, many of its cities offer the world's highest quality of living and remain attractive destinations for expanding business operations and sending expatriates on assignment.

Vienna in Austria took the global number one ranking for the eighth year running.

Other European cities like Zurich (ranked 2 globally), Munich (4), Dusseldorf (6), Geneva (8) and Basel (10) also secured top positions in the survey.

The only non-European cities in the Top 10 are Auckland (ranked 3 globally) and Vancouver (5).

Mercer’s survey also includes a city infrastructure ranking that assesses each city’s supply of electricity, drinking water, telephone and mail services, public transportation, traffic congestion and the range of international flights available from local airports.

Singapore tops the city infrastructure ranking, followed by Frankfurt and Munich, both in second place.

  /theSTAR 15-03-2017
 
Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.


Read more

Pharmaniaga APPL Tender: 2017



Pharmaniaga Bhd plans to launch more products as it anticipates the industry to perform better this year.

Managing director Datuk Farshila Emran said: “Despite the global economic challenges last year, we still did well in 2016 and expect to do better this year.” Pharmaniaga is looking forward to launch more products for cardiovascular, oncology and vaccines as well as its over-the-counter (OTC) products this year.

The company currently has about 430 ethical drugs and OTC products.

Pharmaniaga would be expanding its logistics and distribution business by offering its services to more multinational pharmaceutical companies.

“So, for this year, our capital expenditure is expected to be slightly higher at RM60mil compared with over RM50mil last year,” she said at a briefing on Pharmaniaga’s concession business with the government to facilitate e-Tender exercise for 2017-2019 tender process cycle.

Pharmaniaga is expected to receive about 1,500 tender submissions within the next two days from various potential pharmaceutical and non-pharmaceutical vendors for products listed in the Approved Product Purchase List (APPL) required by the Health Ministry.

As part of its concession agreement with the ministry, Pharmaniaga is required to facilitate the e-Tender exercise for the 2017-2019 tender process cycle.

“APPL e-Tender is not a new exercise. We have undertaken similar exercises every three years, the last one was in 2013. It is aimed at providing a business avenue for the pharmaceutical and non-pharmaceutical vendors to supply products required by the government,” explained Farshila.

As the concession holder, Pharmaniaga has got the consent from the government to carry out the APPL e-Tender procedure. However, the company is not involved in the evaluation and selection stage, which will be managed solely by the government.

“Every step of this exercise, whether via online or offline, will be scrutinised and supervised closely by the officers from the ministry and an external auditor to ensure that it is secured and conducted with integrity and transparent manner,” she added.

 /theSTAR 25-01-2017


Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.


Read more

"Performance Driven Reward" Compensation Package



Performance-driven reward systems will become a norm in workplaces as employers are forced to “rework their compensation packages” to attract and engage with their employees.
This is because salary increases fell by 0.4% to 5.2% last year, according to the 2016 Total Compensation Measurement Survey by Aon Hewitt.
Although the GDP grew at a steady 4.2%, the CPI was 1.8% higher in November last year compared with the figures for the same month in 2015, it said.
“The decline in salary increases translates to real wages diminishing for the Malaysian workforce.
“As a result, employers are pressured to rework their compensation packages to engage their talent more effectively,” said Aon Hewitt, a global talent, retirement, and health solutions business of Aon plc in a statement yesterday.
The survey, which measures how organisations are addressing projected salary budgets, variable pay, and cost-saving initiatives, was based on findings collected from 232 employers nationwide.
The salary trend for fresh graduates, however, remained optimistic as local employers are expected to continue “paying a premium” for jobs in high-tech and engineering related fields.
Fresh graduates in the field of engineering, research and development, and project management were offered the highest starting salaries – over RM3,500 a month – while fresh graduates in high-tech industries are paid 27% more than those in property and construction.
“Throughout the nation, more than half of the fresh graduates entering employment earned less than RM2,500 per month,” it said.
Fresh graduates, although inexperienced, are “digital natives” and that contributed to relevant skills needed in today’s market.

/theSTAR 25-01-2017
 
Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.


Read more

New iPharmacy business model in Australia offers prescription drugs at cost prices.



"When a patient comes to us for help, money is the last thing on our minds,” is how sydneydrugs.com, a new online subscription pharmacy service which launched this week, sells itself to consumers.

The members-only service provides prescription medications at cost price in exchange for an annual subscription fee of $99, $199 or $449 a month, depending on how many extras you want.
“We’re a platform that gives Australians an opportunity to purchase pharmacy items without paying a profit margin to the pharmacy. We are all about making medications affordable,” the site promises.
Customers scan a copy of their prescription or send it in the post, order their drugs online and later receive them in the mail. Any questions they have about the medication are answered within 24 hours.
The website is the brain child of Sydney pharmacists Lindsey Clark and Sunit Ruparelia, who are both registered with industry regulator Australian Health Practitioner Regulation Agency.
Frustrated with the inflated and unpredictable cost of medications, the duo are undercutting local pharmacies and discount retailers like Chemist Warehouse.
“We don’t have overheads like your regular pharmacies do,” Mr Clark told news.com.au.
“Before Sunit became a pharmacist he was diagnosed with high cholesterol and he was sourcing his medication from overseas because of the prices here,” Mr Clark said.
“Working in pharmacies, we see that the prices vary so hugely depending on where you’re located. People in rural towns with only one pharmacy are having to pay so much, while in urban areas the prices are quite competitive.
Mr Clark cited an example of a woman living in a country town currently paying $25 for her medication. “She’s in a town with one pharmacy, so she has to pay it. But we can sell it to her for $4,” he said.
“We’re just offering an option for those people. There’s a lot of struggling families out there.”
Mr Clark says the premises where the drugs are stocked is regularly inspected by the Pharmacy Council of Australia.
But the main industry body is wary about the website. A Pharmacy Guild of Australia spokesman said patients should be “cautious” about a pharmacy model that sidesteps the Pharmaceutical Benefits Scheme, including its safety net provisions.
“While online pharmacy and prescription services may have some benefit for patients in very remote locations, generally Australians are better served by the network of 5600 local pharmacies distributed all over Australia, dispensing subsidised PBS medicines with a Government safety net,” the spokesman said.
“It seems from the list of medicines on the website that many of the more expensive PBS medicines would not be available under the proposed subscription system, so consumers are advised to be cautious.”
/ news.com.au 25-11-2016

Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.


Read more